Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe

Crizotinib (XALKORI(®)) is indicated for anaplastic lymphoma kinase‐positive and ROS1‐positive advanced non‐small cell lung cancer. This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cross‐secti...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kui, Madison, Terri, Wehler, Beatrice, Tiseo, Marcello, Wilner, Keith D., Mo, Jingping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105834/
https://www.ncbi.nlm.nih.gov/pubmed/32232958
http://dx.doi.org/10.1002/prp2.570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105834/
https://www.ncbi.nlm.nih.gov/pubmed/32232958
http://dx.doi.org/10.1002/prp2.570

Ejemplares similares